Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2018 Jun 5;71(22):2497-2506.
doi: 10.1016/j.jacc.2018.01.085.

SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL

Matthew A Cavender  1 , Anna Norhammar  2 , Kåre I Birkeland  3 , Marit Eika Jørgensen  4 , John P Wilding  5 , Kamlesh Khunti  6 , Alex Z Fu  7 , Johan Bodegård  8 , Betina T Blak  9 , Eric Wittbrodt  10 , Marcus Thuresson  11 , Peter Fenici  12 , Niklas Hammar  13 , Mikhail Kosiborod  14 ; CVD-REAL Investigators and Study Group
Collaborators, Affiliations
Free article
Observational Study

SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL

Matthew A Cavender et al. J Am Coll Cardiol. .
Free article

Abstract

Background: Prior studies found patients treated with sodium-glucose co-transporter-2 inhibitors (SGLT-2i) had lower rates of death and heart failure (HF). Whether the benefits of SGLT-2i vary based upon the presence of cardiovascular disease (CVD) is unknown.

Objectives: This study sought to determine the association between initiation of SGLT-2i therapy and HF or death in patients with and without CVD.

Methods: The CVD-REAL (Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors) study was a multinational, observational study in which adults with type 2 diabetes were identified. Patients prescribed an SGLT-2i or other glucose-lowering drugs (GLDs) were matched based on a propensity score for initiation of an SGLT-2i. Hazard ratios (HRs) for the risk of death, HF, and HF or death in patients with and without established CVD were estimated for each country and pooled.

Results: After propensity score matching, 153,078 patients were included in each group. At baseline, 13% had established CVD. Compared with therapy using other GLDs, initiation of an SGLT-2i was associated with lower risk of death in patients with and without CVD (HR: 0.56; 95% confidence interval [CI]: 0.44 to 0.70; and HR: 0.56; 95% CI: 0.50 to 0.63, respectively). There were also associations between SGLT-2i and lower risk of HF (HR: 0.72; 95% CI: 0.63 to 0.82; and HR: 0.61; 95% CI: 0.48 to 0.78, respectively) and the composite of HF or death (HR: 0.63; 95% CI: 0.57 to 0.70; and HR: 0.56; 95% CI: 0.50 to 0.62, respectively) observed in patients with and without established CVD.

Conclusions: In this large, multinational, observational study, initiation of SGLT-2i was associated with lower risk of death and HF regardless of pre-existing CVD. Ongoing clinical trials will provide further evidence regarding the benefit of SGLT-2i in patients without established CVD. (Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors [CVD-REAL]; NCT02993614).

Keywords: CVD-REAL; cardiovascular disease; heart failure; sodium-glucose co-transporter-2 inhibitors.

PubMed Disclaimer

Comment in

Substances

Associated data